← Browse by Condition
Medical Condition

advanced solid tumor

Total Trials
33
Recruiting Now
33
Trial Phases
Phase 1, Phase 2, Phase 1, EARLY_Phase 1

ClinicalMetric tracks all active clinical trials for advanced solid tumor sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — advanced solid tumor Clinical Trials

How many clinical trials are currently recruiting for advanced solid tumor?
ClinicalMetric currently tracks 33 actively recruiting clinical trials for advanced solid tumor, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 33. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for advanced solid tumor?
advanced solid tumor research spans Phase 1 (32 trials), Phase 2 (10 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a advanced solid tumor clinical trial?
Eligibility criteria for advanced solid tumor trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
32
Phase 2
10
Top Sponsors
BeOne Medicines 2 trials
China-Japan Friendship Hospital 1 trial
University of Chicago 1 trial
Fate Therapeutics 1 trial
Peking University 1 trial

Recruiting Clinical Trials

NCT06173219 Phase 1, Phase 2
Recruiting
Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors.
Enrollment
38 pts
Location
China
Sponsor
China-Japan Friendship Hospita...
View Trial →
NCT05166694
Recruiting
Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions
Enrollment
1,300 pts
Location
United States
Sponsor
University of Chicago
View Trial →
NCT06241456 Phase 1
Recruiting
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Enrollment
351 pts
Location
United States
Sponsor
Fate Therapeutics
View Trial →
NCT06170294 Phase 1
Recruiting
MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors
Enrollment
20 pts
Location
China
Sponsor
Peking University
View Trial →
NCT05867251 Phase 1, Phase 2
Recruiting
Study of AVZO-021 in Patients With Advanced Solid Tumors
Enrollment
430 pts
Location
United States, Austr...
Sponsor
Avenzo Therapeutics, Inc.
View Trial →
NCT06825494 Phase 1, Phase 2
Recruiting
Clinical Studies for the Treatment of Advanced Solid Tumors
Enrollment
194 pts
Location
China
Sponsor
Chia Tai Tianqing Pharmaceutic...
View Trial →
NCT06257680 Phase 1
Recruiting
A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors
Enrollment
15 pts
Location
China
Sponsor
Beijing Xunsheng Biomedical Re...
View Trial →
NCT07128303 Phase 1
Recruiting
Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors
Enrollment
476 pts
Location
United States, South...
Sponsor
Gilead Sciences
View Trial →
NCT07110883 Phase 1
Recruiting
A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors
Enrollment
400 pts
Location
China
Sponsor
CSPC Megalith Biopharmaceutica...
View Trial →
NCT05156203 Phase 1
Recruiting
Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors
Enrollment
30 pts
Location
Taiwan
Sponsor
Taivex Therapeutics Corporatio...
View Trial →
NCT05547321 Phase 1
Recruiting
Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.
Enrollment
150 pts
Location
United States, Spain
Sponsor
Oncomatryx Biopharma S.L.
View Trial →
NCT06258408 Phase 1
Recruiting
A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors
Enrollment
78 pts
Location
China
Sponsor
Broadenbio Ltd., Co.
View Trial →
NCT05038150 Phase 1, Phase 2
Recruiting
Study of SGN1 in Patients With Advanced Solid Tumor
Enrollment
70 pts
Location
United States, China
Sponsor
Guangzhou Sinogen Pharmaceutic...
View Trial →
NCT05761223 Phase 1, Phase 2
Recruiting
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
Enrollment
151 pts
Location
United States
Sponsor
1ST Biotherapeutics, Inc.
View Trial →
NCT05725291 Phase 1
Recruiting
AMT-116 in Patients With Advanced Solid Tumors
Enrollment
80 pts
Location
United States, Ameri...
Sponsor
Multitude Therapeutics Inc.
View Trial →
NCT06973863 Phase 1
Recruiting
A Study of PEP08 in Patients With MTAP-Del Advanced or Metastatic Solid Tumors
Enrollment
40 pts
Location
Australia, Taiwan
Sponsor
PharmaEngine
View Trial →
NCT06108050 Phase 1
Recruiting
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
Enrollment
177 pts
Location
United States
Sponsor
Jazz Pharmaceuticals
View Trial →
NCT07181681 Phase 1
Recruiting
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
Enrollment
63 pts
Location
United States, Austr...
Sponsor
BeOne Medicines
View Trial →
NCT07298772 Phase 1, Phase 2
Recruiting
A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors
Enrollment
198 pts
Location
China
Sponsor
Suzhou Suncadia Biopharmaceuti...
View Trial →
NCT07541573 Phase 1
Recruiting
GTB-5550 in Advanced Solid Tumors
Enrollment
175 pts
Location
United States
Sponsor
Masonic Cancer Center, Univers...
View Trial →
NCT06771219 Phase 1
Recruiting
SLV-154 Treatment of Advanced Cancers
Enrollment
250 pts
Location
United States
Sponsor
Solve Therapeutics
View Trial →
NCT07348653 Phase 1
Recruiting
A Study of MG2512 Injection in Participants With Advanced Solid Tumors
Enrollment
116 pts
Location
China
Sponsor
Shanghai Mabgen Biopharmaceuti...
View Trial →
NCT07124117 Phase 1, Phase 2
Recruiting
A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors
Enrollment
147 pts
Location
United States, Taiwa...
Sponsor
OBI Pharma, Inc
View Trial →
NCT04999384 Phase 1
Recruiting
First in Human, Dose Escalation Study of AN4005
Enrollment
31 pts
Location
United States, China
Sponsor
Adlai Nortye Biopharma Co., Lt...
View Trial →
NCT06859762 Phase 1
Recruiting
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
Enrollment
630 pts
Location
United States, China
Sponsor
MediLink Therapeutics (Suzhou)...
View Trial →
NCT06465069 Phase 1
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Enrollment
460 pts
Location
United States, Austr...
Sponsor
Eli Lilly and Company
View Trial →
NCT07629960 Phase 1, Phase 2
Recruiting
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Enrollment
265 pts
Location
United States, Spain
Sponsor
Blueprint Medicines Corporatio...
View Trial →
NCT04471987 Phase 1
Recruiting
Safety and Early Signs of Efficacy of IL12-L19L19.
Enrollment
80 pts
Location
Germany, Italy, Swit...
Sponsor
Philogen S.p.A.
View Trial →
NCT05269316 Phase 1, Phase 2
Recruiting
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Enrollment
61 pts
Location
United States, Austr...
Sponsor
Impact Therapeutics, Inc.
View Trial →
NCT05320588 Phase 1, Phase 2
Recruiting
A Study in Patients With Advanced Cancers
Enrollment
332 pts
Location
United States
Sponsor
BiOneCure Therapeutics Inc.
View Trial →
NCT05765851 Phase 1
Recruiting
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
Enrollment
128 pts
Location
United States, Canad...
Sponsor
Daiichi Sankyo
View Trial →
NCT06120283 Phase 1
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Enrollment
433 pts
Location
United States, Austr...
Sponsor
BeOne Medicines
View Trial →
NCT07793500 EARLY_Phase 1
Recruiting
YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC)
Enrollment
36 pts
Location
China
Sponsor
Cancer Institute and Hospital,...
View Trial →

Related Conditions

advanced cancer (3) metastatic solid tumor (3) cancer (2) solid tumors (2) solid tumor (2) non small cell lung cancer (2) mental health issue (1) behavior disorders (1) hr her2 breast cancer (1) hr her2 advanced breast cancer (1) ccne1 amplification (1) epithelial ovarian cancer (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology